Prostacyclin's Effect on Platelet Responsiveness
Information source: Catholic University of the Sacred Heart
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Kidney Failure
Intervention: prostacyclin (Drug); heparin (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Catholic University of the Sacred Heart Official(s) and/or principal investigator(s): Massimo Antonelli, MD, Study Director, Affiliation: Istituto Anestesia e Rianimazione Università Cattolica Policlinico Gemelli
Summary
The researchers investigated the influence of a prostacyclin analogue (PGIA) versus
unfractionated heparin (UFH) on ex vivo platelet function, during continuous venovenous
hemodiafiltration.
Clinical Details
Official title: Heparin Versus Prostacyclin in Continuous Hemodiafiltration for Acute Renal Failure: Effects on Platelet Responsiveness in the Systemic Circulation and Across the Filter.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Detailed description:
Context and purpose of the study: Prospective, randomized comparison of a PGIA versus UFH as
circuit anticoagulant. Platelet responsiveness was assessed from peripheral blood by
light-transmittance aggregometry (LTA) induced by collagen and ADP, at baseline, 4 and 24
hrs after treatment onset. Platelet function was also assessed in blood samples collected
in the circuit before and after the filter. The Setting was a University Hospital Intensive
Care Unit. 23 ICU patients with Acute Renal Failure needing CVVHDF were studied during
standard CVVHDF therapy, at random infusion in the extracorporeal circuit of PGIA or UFH.
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- critically patients ill patients with acute kidney failure (AKI) needing renal
replacement therapy
Exclusion Criteria:
- therapy with aspirin or other non-steroidal anti-inflammatory drugs in the previous 7
days
- concomitant treatment with other extracorporeal organ-assist devices any other drug
affecting coagulation or platelets
Locations and Contacts
Policlinico Gemelli, Rome 00168, Italy
Additional Information
Starting date: September 2007
Last updated: April 28, 2009
|